From: The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Covariate | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
p-value | HR | 95% CI | p-value | HR | 95% CI | |
PFS | ||||||
Gender | 0.544 | 1.168 | 0.705–1.935 | 0.614 | 1.145 | 0.676–1.936 |
T2D | 0.019 | 1.285 | 1.040–1.586 | 0.035 | 1.680 | 1.036–2.720 |
First-line treatment | 0.033 | 0.607 | 0.384–0.960 | 0.050 | 0.614 | 0.377–1.000 |
ECOG PS > 2 | 0.660 | 1.131 | 0.651–1.966 | 0.345 | 1.343 | 0.727–2.476 |
LDH | 0.002 | 1.906 | 1.253–2.900 | 0.021 | 1.706 | 1.080–2.692 |
OS | ||||||
Gender | 0.780 | 1.085 | 0.610–1.930 | 0.613 | 1.165 | 0.643–2.108 |
T2D | 0.032 | 1.310 | 1.022–1.679 | 0.050 | 1.727 | 1.000–2.981 |
First-line treatment | 0.185 | 0.698 | 0.410–1.189 | 0.249 | 0.719 | 0.409 – 1.261 |
ECOG PS > 2 | 0.835 | 1.074 | 0.548–2.105 | 0.311 | 1.472 | 0.696–3.110 |
LDH | 0.0001 | 2.683 | 1.617–4.451 | 0.0007 | 2.572 | 1.493–4.430 |